Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 7—July 2003
Research

Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance

Sue Lim*†, Darrin Bast*†, Allison McGeer*†, Joyce de Azavedo*†, and Donald E. Low*†Comments to Author 
Author affiliations: *Toronto Medical Laboratories/Mount Sinai Hospital, Toronto, Ontario, Canada; †University of Toronto, Toronto, Ontario, Canada

Main Article

Table 1

ParC amino acid substitutions found in 115 Streptococcus pneumoniae isolates with levofloxacin MICs >2 μg/mL and corresponding levofloxacin MICs

ParC amino acid substitution No. isolates inhibited by levofloxacin MIC (µg/mL) of
Total no. of strains
2 4 8 16 ≥32
Ser79→Phe 28 4 3 9 3 47
Ser79→Tyr 7 1 3 2 1 14
Ser79→Ala 1 0 0 0 0 1
Asp83→Asn 7 0 3 0 0 10
Asp83→Gly 1 0 0 0 0 1
Asp83→Tyr 3 0 0 0 0 3
Asp83→Val 1 0 0 0 0 1
Asp83→Ala 0 0 1 0 0 1
No. isolates/total with amino acid substitutions 48/82 (59%) 5/8a (63%) 10/10 11/11 4/4 78/115 (69%)

aOne isolate with no ParC amino acid substitution found to have active efflux; two isolates had ParC amino acid substitutions at sites other than Ser79 or Asp83.

Main Article

Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external